Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24035067 | 0.83 | — | — | |
| SCHEMBL2873742 | 0.79 | PGD (0.37) | MAPK1 | |
| SCHEMBL8245161 | 0.79 | PGD (0.37) | MAPK1 | |
| SCHEMBL23128331 | 0.77 | LMNA (0.33) | MAPK1 | |
| SCHEMBL30861202 | 0.77 | LMNA (0.33) | MAPK1 | |
| SCHEMBL16478507 | 0.76 | TSHR (0.39) | — | |
| SCHEMBL12640767 | 0.73 | — | — | |
| SCHEMBL16342321 | 0.72 | MAPT (0.40) | — | |
| SCHEMBL14469851 | 0.72 | — | — | |
| SCHEMBL716280 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034645-B2 | Treprostinil derivatives and compositions and uses thereof | Corsair Pharma, Inc. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10759733-B2 | Treprostinil derivatives and compositions and uses thereof | Corsair Pharma, Inc. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10703706-B2 | Treprostinil derivatives and compositions and uses thereof | Corsair Pharma, Inc. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200095186-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | Corsair Pharma, Inc. (US) | 2020-03-26 | — | — | US | disclosed |
| US-20200071257-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | Corsair Pharma, Inc. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20190241499-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | CORSAIR PHARMA INC (US) | 2019-08-08 | — | — | US | disclosed |
| US-10246403-B2 | Treprostinil derivatives and compositions and uses thereof | Corsair Pharma, Inc. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20180170855-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | Corsair Pharma, Inc. | 2018-06-21 | — | — | US | disclosed |
| US-9957220-B2 | Treprostinil derivatives and compositions and uses thereof | Corsair Pharma, Inc. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20180016222-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | Corsair Pharma, Inc. | 2018-01-18 | — | — | US | disclosed |
| US-20170298001-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | CORSAIR PHARMA INC (US) | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071257-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | PTGIS, PTGIR, PDE3A | MAPK1 2403/4885 |
| US-10246403-B2 | Treprostinil derivatives and compositions and uses thereof | PTGIS, PTGIR, PDE3A | MAPK1 2403/4885 |
| US-20190241499-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | PTGIS, PTGIR, PDE3A | MAPK1 2403/4885 |
| US-10703706-B2 | Treprostinil derivatives and compositions and uses thereof | PTGIS, PTGIR, PDE3A | MAPK1 2403/4885 |
| US-20170298001-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | PTGIS, PTGIR, PDE3A | MAPK1 2403/4885 |
| US-20180016222-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | PTGIS, PTGIR, PDE3A | MAPK1 2403/4885 |
| US-10759733-B2 | Treprostinil derivatives and compositions and uses thereof | PTGIS, PTGIR, PDE3A | MAPK1 2403/4885 |
| US-20180170855-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | PTGIS, PTGIR, PDE3A | MAPK1 2403/4885 |
| US-11034645-B2 | Treprostinil derivatives and compositions and uses thereof | PTGIS, PTGIR, PDE3A | MAPK1 2403/4885 |
| US-20200095186-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | PTGIS, PTGIR, PDE3A | MAPK1 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.